The uterine fibroid embolization device market size has grown steadily in recent years. It will grow from $5.93 billion in 2025 to $6.19 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to rising prevalence of uterine fibroids among women of reproductive age, growing number of hospital and clinic-based gynecological procedures, increasing adoption of uterine artery embolization in interventional radiology, greater awareness of alternatives to open surgical myomectomy, expansion of minimally invasive treatment workflows in tertiary care centers.
The uterine fibroid embolization device market size is expected to see steady growth in the next few years. It will grow to $7.33 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to rising demand for uterus-sparing fibroid treatments in younger patient populations, growing clinical shift toward minimally invasive and non-invasive treatment modes, increasing procedural penetration in ambulatory surgical centers, expanding use of ablation and embolization devices for fibroid size reduction, rising investments in advanced delivery catheters and embolic systems to improve treatment precision. Major trends in the forecast period include rising adoption of minimally invasive embolization techniques for uterine fibroid treatment, increasing clinical preference for organ-preserving alternatives to hysterectomy, growing utilization of image-guided interventional devices for targeted fibroid therapy, expanding use of embolization procedures in outpatient and ambulatory surgical settings, increasing demand for precision delivery systems to improve procedural safety and outcomes.
The growing demand for minimally invasive surgeries is expected to drive the growth of the uterine fibroid embolization device market. Minimally invasive surgeries involve small incisions or the use of natural body openings to access and treat internal organs, tissues, or structures while minimizing trauma to the patient. The demand for these procedures is increasing as patients and healthcare providers seek treatments that reduce recovery time, lower complication risks, and improve overall comfort. Uterine fibroid embolization devices facilitate these procedures by enabling precise and effective treatment of fibroids, improving patient outcomes and procedural efficiency. For instance, in January 2025, according to AOS Open, a US-based medical journal, hospitals with robotic-assisted systems reported that minimally invasive surgeries accounted for 65.8% of procedures in 2025, up from 60.5% in 2022. Therefore, the growing demand for minimally invasive surgeries is propelling the uterine fibroid embolization device market.
Companies in this market are focusing on innovations such as minimally invasive fibroid management software to improve precision and efficiency in uterine fibroid treatment. This type of software provides clinicians with advanced digital tools to plan, guide, and execute minimally invasive procedures, enhancing procedural accuracy, safety, and patient outcomes. For example, in September 2024, Gynesonics, a US-based medical device company specializing in minimally invasive gynecologic treatments, launched SMART OS 2.4 software for the Sonata System. The software reduces the minimum ablation zone size from 2 × 1.3 cm to 1.6 × 1.2 cm, decreases ablation volume by 38%, and optimizes the Thermal Safety Border for smaller fibroids, enabling more controlled treatments while preserving healthy uterine tissue.
In October 2024, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. This acquisition expands Hologic’s portfolio of minimally invasive treatment options for women’s health, particularly in the management of uterine fibroids and heavy menstrual bleeding. Gynesonics develops minimally invasive solutions for the treatment of symptomatic uterine fibroids, and its integration strengthens Hologic’s position in the women’s health market.
Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC.
North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uterine fibroid embolization device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the uterine fibroid embolization device market by increasing the import and manufacturing costs of embolic agents, microcatheters, delivery systems, and imaging-guided interventional components, leading to higher procedure costs across hospitals, clinics, and ambulatory surgical centers. The effect is more pronounced in regions relying on cross-border sourcing of interventional radiology devices, particularly in North America, Europe, and Asia-Pacific specialty care markets. Segments such as embolization techniques and minimally invasive treatment systems experience the strongest pricing pressure; however, tariffs are also encouraging domestic assembly, regional supply localization, and innovation in cost-efficient device design, which supports long-term supply resilience and market competitiveness.
The uterine fibroid embolization device market research report is one of a series of new reports that provides uterine fibroid embolization device market statistics, including uterine fibroid embolization device industry global market size, regional shares, competitors with a uterine fibroid embolization device market share, detailed uterine fibroid embolization device market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid embolization device industry. This uterine fibroid embolization device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A uterine fibroid embolization device is a medical device used in the treatment of noncancerous tumors, specifically uterine fibroids, through a minimally invasive procedure. Uterine fibroids are benign growths in the uterus, and this device functions by restricting the blood supply to these fibroids, causing them to shrink and ultimately disappear.
The main types of technologies associated with uterine fibroid embolization devices include surgical techniques, laparoscopic techniques, ablation techniques, and embolization techniques. Surgical techniques involve specific methods and procedures employed by medical professionals. These devices are utilized in various treatment modes, including invasive, minimally invasive, and non-invasive treatments. Additionally, they find application in diverse healthcare settings such as hospitals, clinics, and ambulatory surgical centers.
The uterine fibroid embolization device market consists of revenues earned by entities by provide services such as minimally invasive procedures, non-invasive procedures, minimally invasive procedures, radiofrequency ablation, medication and hormonal therapy, and embolization procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The uterine fibroid embolization device market also includes sales of medications, hysteroscopic devices, laparoscopic devices, radiofrequency ablation devices, endometrial ablation devices, hysterectomy devices, and robotic surgical systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The uterine fibroid embolization device market size is expected to see steady growth in the next few years. It will grow to $7.33 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to rising demand for uterus-sparing fibroid treatments in younger patient populations, growing clinical shift toward minimally invasive and non-invasive treatment modes, increasing procedural penetration in ambulatory surgical centers, expanding use of ablation and embolization devices for fibroid size reduction, rising investments in advanced delivery catheters and embolic systems to improve treatment precision. Major trends in the forecast period include rising adoption of minimally invasive embolization techniques for uterine fibroid treatment, increasing clinical preference for organ-preserving alternatives to hysterectomy, growing utilization of image-guided interventional devices for targeted fibroid therapy, expanding use of embolization procedures in outpatient and ambulatory surgical settings, increasing demand for precision delivery systems to improve procedural safety and outcomes.
The growing demand for minimally invasive surgeries is expected to drive the growth of the uterine fibroid embolization device market. Minimally invasive surgeries involve small incisions or the use of natural body openings to access and treat internal organs, tissues, or structures while minimizing trauma to the patient. The demand for these procedures is increasing as patients and healthcare providers seek treatments that reduce recovery time, lower complication risks, and improve overall comfort. Uterine fibroid embolization devices facilitate these procedures by enabling precise and effective treatment of fibroids, improving patient outcomes and procedural efficiency. For instance, in January 2025, according to AOS Open, a US-based medical journal, hospitals with robotic-assisted systems reported that minimally invasive surgeries accounted for 65.8% of procedures in 2025, up from 60.5% in 2022. Therefore, the growing demand for minimally invasive surgeries is propelling the uterine fibroid embolization device market.
Companies in this market are focusing on innovations such as minimally invasive fibroid management software to improve precision and efficiency in uterine fibroid treatment. This type of software provides clinicians with advanced digital tools to plan, guide, and execute minimally invasive procedures, enhancing procedural accuracy, safety, and patient outcomes. For example, in September 2024, Gynesonics, a US-based medical device company specializing in minimally invasive gynecologic treatments, launched SMART OS 2.4 software for the Sonata System. The software reduces the minimum ablation zone size from 2 × 1.3 cm to 1.6 × 1.2 cm, decreases ablation volume by 38%, and optimizes the Thermal Safety Border for smaller fibroids, enabling more controlled treatments while preserving healthy uterine tissue.
In October 2024, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. This acquisition expands Hologic’s portfolio of minimally invasive treatment options for women’s health, particularly in the management of uterine fibroids and heavy menstrual bleeding. Gynesonics develops minimally invasive solutions for the treatment of symptomatic uterine fibroids, and its integration strengthens Hologic’s position in the women’s health market.
Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC.
North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uterine fibroid embolization device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the uterine fibroid embolization device market by increasing the import and manufacturing costs of embolic agents, microcatheters, delivery systems, and imaging-guided interventional components, leading to higher procedure costs across hospitals, clinics, and ambulatory surgical centers. The effect is more pronounced in regions relying on cross-border sourcing of interventional radiology devices, particularly in North America, Europe, and Asia-Pacific specialty care markets. Segments such as embolization techniques and minimally invasive treatment systems experience the strongest pricing pressure; however, tariffs are also encouraging domestic assembly, regional supply localization, and innovation in cost-efficient device design, which supports long-term supply resilience and market competitiveness.
The uterine fibroid embolization device market research report is one of a series of new reports that provides uterine fibroid embolization device market statistics, including uterine fibroid embolization device industry global market size, regional shares, competitors with a uterine fibroid embolization device market share, detailed uterine fibroid embolization device market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid embolization device industry. This uterine fibroid embolization device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A uterine fibroid embolization device is a medical device used in the treatment of noncancerous tumors, specifically uterine fibroids, through a minimally invasive procedure. Uterine fibroids are benign growths in the uterus, and this device functions by restricting the blood supply to these fibroids, causing them to shrink and ultimately disappear.
The main types of technologies associated with uterine fibroid embolization devices include surgical techniques, laparoscopic techniques, ablation techniques, and embolization techniques. Surgical techniques involve specific methods and procedures employed by medical professionals. These devices are utilized in various treatment modes, including invasive, minimally invasive, and non-invasive treatments. Additionally, they find application in diverse healthcare settings such as hospitals, clinics, and ambulatory surgical centers.
The uterine fibroid embolization device market consists of revenues earned by entities by provide services such as minimally invasive procedures, non-invasive procedures, minimally invasive procedures, radiofrequency ablation, medication and hormonal therapy, and embolization procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The uterine fibroid embolization device market also includes sales of medications, hysteroscopic devices, laparoscopic devices, radiofrequency ablation devices, endometrial ablation devices, hysterectomy devices, and robotic surgical systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Uterine Fibroid Embolization Device Market Characteristics
3. Uterine Fibroid Embolization Device Market Supply Chain Analysis
4. Global Uterine Fibroid Embolization Device Market Trends and Strategies
5. Uterine Fibroid Embolization Device Market Analysis of End Use Industries
7. Global Uterine Fibroid Embolization Device Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Uterine Fibroid Embolization Device Total Addressable Market (TAM) Analysis for the Market
9. Uterine Fibroid Embolization Device Market Segmentation
10. Uterine Fibroid Embolization Device Market Regional and Country Analysis
11. Asia-Pacific Uterine Fibroid Embolization Device Market
12. China Uterine Fibroid Embolization Device Market
13. India Uterine Fibroid Embolization Device Market
14. Japan Uterine Fibroid Embolization Device Market
15. Australia Uterine Fibroid Embolization Device Market
16. Indonesia Uterine Fibroid Embolization Device Market
17. South Korea Uterine Fibroid Embolization Device Market
18. Taiwan Uterine Fibroid Embolization Device Market
19. South East Asia Uterine Fibroid Embolization Device Market
20. Western Europe Uterine Fibroid Embolization Device Market
21. UK Uterine Fibroid Embolization Device Market
22. Germany Uterine Fibroid Embolization Device Market
23. France Uterine Fibroid Embolization Device Market
24. Italy Uterine Fibroid Embolization Device Market
25. Spain Uterine Fibroid Embolization Device Market
26. Eastern Europe Uterine Fibroid Embolization Device Market
27. Russia Uterine Fibroid Embolization Device Market
28. North America Uterine Fibroid Embolization Device Market
29. USA Uterine Fibroid Embolization Device Market
30. Canada Uterine Fibroid Embolization Device Market
31. South America Uterine Fibroid Embolization Device Market
32. Brazil Uterine Fibroid Embolization Device Market
33. Middle East Uterine Fibroid Embolization Device Market
34. Africa Uterine Fibroid Embolization Device Market
36. Uterine Fibroid Embolization Device Market Competitive Landscape and Company Profiles
37. Uterine Fibroid Embolization Device Market Other Major and Innovative Companies
40. Uterine Fibroid Embolization Device Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Uterine Fibroid Embolization Device Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses uterine fibroid embolization device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for uterine fibroid embolization device? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The uterine fibroid embolization device market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology: Surgical Techniques; Laparoscopic Techniques; Ablation Techniques; Embolization Techniques2) By Mode Of Treatment: Invasive Treatment; Minimally Invasive Treatment
3) By End User: Hospitals; Clinics; Ambulatory Surgical Center
Subsegments:
1) By Surgical Techniques: Open Surgery; Myomectomy2) By Laparoscopic Techniques: Laparoscopic Myomectomy; Laparoscopic Hysterectomy
3) By Ablation Techniques: Radiofrequency Ablation; Microwave Ablation; Cryoablation
4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE); Uterine Artery Embolization (UAE)
Companies Mentioned: Johnson and Johnson Pvt Ltd.; Medtronic plc.; Boston Scientific Corporation; Olympus Corporation; Terumo Corporation; Ethicon Inc.; Hologic Inc.; CooperSurgical Inc.; Cook Medical Inc.; Karl Storz GmbH; Merit Medical Systems; CONMED Corporation; Lumenis Ltd.; Richard Wolf GmbH; BTG International Ltd.; Healthium MedTech Pvt. Ltd.; Hironic Co.Ltd; Minerva Surgical Inc.; Gynesonics Inc.; Advanced Surgical Concepts PLLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Uterine Fibroid Embolization Device market report include:- Johnson and Johnson Pvt Ltd.
- Medtronic plc.
- Boston Scientific Corporation
- Olympus Corporation
- Terumo Corporation
- Ethicon Inc.
- Hologic Inc.
- CooperSurgical Inc.
- Cook Medical Inc.
- Karl Storz GmbH
- Merit Medical Systems
- CONMED Corporation
- Lumenis Ltd.
- Richard Wolf GmbH
- BTG International Ltd.
- Healthium MedTech Pvt. Ltd.
- Hironic Co.Ltd
- Minerva Surgical Inc.
- Gynesonics Inc.
- Advanced Surgical Concepts PLLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.19 Billion |
| Forecasted Market Value ( USD | $ 7.33 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
